Centre Hospitalier Universitaire De Bordeaux
- Address
- lock Available on a paid plan
Oncology and Melanoma Research
The Oncology program at Centre Hospitalier Universitaire De Bordeaux includes a strong focus on neoplasms, especially melanoma, renal cell carcinoma, and head and neck cancers. These studies are designed to evaluate new immunotherapy approaches, improve recurrence prevention, and compare treatment effectiveness in advanced or resected disease.
- Advanced and metastatic melanoma, including recurrence prevention after surgery
- Renal cell carcinoma and other advanced solid tumors
- Head and neck squamous cell carcinoma and related malignancies
This research reflects a broad effort to test innovative cancer therapies and improve outcomes for patients with difficult-to-treat tumors.
Skin and Immune-Mediated Disease Studies
A substantial part of the site’s clinical research addresses skin and connective tissue diseases and immune system diseases, including atopic dermatitis, hidradenitis suppurativa, prurigo nodularis, and alopecia areata. The trials aim to assess symptom control, long-term disease management, and the effectiveness of new or established treatments.
- Atopic dermatitis in adolescents and adults
- Hidradenitis suppurativa and prurigo nodularis
- Alopecia areata and vitiligo
These studies are centered on improving quality of life by testing therapies that may better control chronic inflammatory skin conditions.
Virus-Related and Preventive Immunology Research
The site also conducts studies in virus diseases and broader immune system diseases, including HIV and vaccine-response research. At Centre Hospitalier Universitaire De Bordeaux, this work explores how well preventive or immune-based strategies perform in people living with chronic viral infection and related health conditions.
- HIV-1 infection and long-term treatment follow-up
- Recombinant zoster vaccine immune response in older adults living with HIV
- Supportive immunology studies in people with chronic infection
The goal is to better understand immune protection and strengthen preventive care in populations with ongoing viral health needs.
Autoimmune, Eye, and Inflammatory Disease Trials
Research here extends beyond cancer into immune system diseases, eye diseases, and other chronic inflammatory conditions such as giant cell arteritis, Sjögren’s syndrome, and non-infectious uveitis. These trials are focused on evaluating treatment effectiveness, maintaining remission, and reducing disease activity over time.
- Giant cell arteritis and treatment discontinuation strategies
- Sjögren’s syndrome and inflammatory control
- Uveitis and related eye disease management
This work supports more personalized care for patients with autoimmune and inflammatory disorders that can affect vision, comfort, and daily function.
Digestive and Male Urogenital Cancer Research
The clinical trial portfolio also includes digestive system diseases and male urogenital diseases, with studies in hepatocellular carcinoma, germ-cell tumors, and other advanced malignancies. These trials are intended to test new combinations, refine treatment strategies, and improve survival in aggressive cancers.
- Unresectable hepatocellular carcinoma
- Non-seminomatous germ-cell tumors
- Other advanced or metastatic solid tumors
The research reflects a commitment to expanding options for patients facing complex cancers with limited standard treatments.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 36 therapeutic areas and 15 of 959 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 894 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 206 by active trials.
lock +205 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Assistance Publique Hopitaux De Paris100trials
lock +121 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Universitaire De Bordeaux
lock Showing 1 of 975 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 959 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 53 | Unknown | 2015-07-16 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.